Our proprietary AI model analyzes vast datasets of antibody sequences and their corresponding affinities.
We integrate real-world biological data with advanced machine learning algorithms to predict critical antibody properties.
This unique approach streamlines candidate selection, dramatically reducing discovery timelines.

We collect massive datasets of antibody sequences linked to real-world binding affinity measurements.
Our models predict antibody properties like specificity, affinity, stability, and manufacturability.
Algorithms identify promising candidates before expensive lab testing begins.
Validated candidates move quickly to optimization and clinical development.
Target antigens are used to stimulate immune responses in humanized models, generating diverse antibody repertoires against specific disease targets.
Individual B cells that produce antibodies with desired binding properties are isolated using high-throughput fluorescence-activated cell sorting.
Isolated B cells undergo deep sequencing to identify unique antibody gene sequences with exceptional precision and coverage.
Comprehensive analysis correlates B cell receptor sequences with binding affinities, enriching our AI platform with real-world biological data.
Targeting complex neurodegenerative disorders with precision antibodies that cross the blood-brain barrier.
Developing neutralizing antibodies against emerging viral and bacterial pathogens with pandemic potential.
Creating targeted immunotherapies that precisely engage cancer cells while sparing healthy tissue.
We envision a world where antibody therapeutics are developed in months, not years, delivering transformative treatments to patients faster than ever before.
Revolutionize the speed and precision of antibody drug discovery through AI-driven insights.
Bridge computational innovation with biological reality to address unmet medical needs.
Deliver safer, more effective antibody therapies to patients worldwide.
Founded by experts in computational biology, AI engineering, and antibody development with decades of combined experience.
All discoveries validated through strict experimental protocols and peer review.
Working with global academic and industry partners to advance therapeutic innovation.
Every decision guided by our mission to improve patient outcomes worldwide.
Email: info@shafaai.io
Phone: +1 (650) 273-7411‪
Address: 1030 Brittan Ave. San Carlos, CA 94070

Follow us on LinkedIn and Twitter for the latest updates on our platform and pipeline developments.
Transforming antibody therapeutics with our AI platform trained on real-world data, targeting neurology, infectious diseases, and oncology.